Welcome to our dedicated page for Aadi Bioscience news (Ticker: $AADI), a resource for investors and traders seeking the latest updates and insights on Aadi Bioscience stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Aadi Bioscience's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Aadi Bioscience's position in the market.
Aadi Bioscience, a precision oncology company, announced Q1 2024 financial results with FYARRO sales of $5.4 million. The PRECISION1 trial is fully enrolled, with an interim analysis planned for Q3 2024. Phase 2 trials in EEC and NETs are progressing well. Despite an 8.8% decrease in sales due to distributor patterns, FYARRO continues to be a preferred PEComa treatment. The company ended Q1 with $88.3 million in cash. A conference call will discuss these updates.
Aadi Bioscience, a precision oncology company, will report its Q1 2024 results and provide corporate updates on May 8, 2024. The company focuses on developing therapies for cancers with alterations in the mTOR pathway. A conference call and webcast will be held, allowing participants to access the call through the company's website or via telephone registration. A replay will be available for 30 days.
